News

Governor Youngkin Announces Expansion of Life Sciences in Prince William County, Creating up to 70 New Jobs

~ Virongy Biosciences Inc. to invest $471,000 to begin development of diagnostic technologies for viral pathogens ~

RICHMOND, VA – Governor Glenn Youngkin announced that Virongy Biosciences Inc., a developer of viral diagnostic technologies, anti-viral drugs, and therapeutic viral vectors, will invest $471,000 to expand in Prince William County. The company recently relocated to occupy over 2,000 square feet of the Northern Virginia Bioscience Center, where it will begin to develop new diagnostic technologies to monitor and quantify SARS-CoV-2 variants and other viral pathogens. The expansion project will create up to 70 new jobs.
“Prince William County has emerged as a hub for the life sciences industry, offering the infrastructure, R&D assets, and talent to attract and retain innovative biotech firms like Virongy,” said Governor Youngkin. “We applaud the company for its groundbreaking developments that will have a positive and far-reaching impact on bioscience advancements and disease prevention and treatment.”
“Virongy’s expansion in Prince William County reinforces the region’s robust industry talent, world-class education institutions, and advanced culture of innovation that supports the company’s mission,” said Secretary of Commerce and Trade Caren Merrick. “We thank Virongy for creating valuable jobs while improving the health of our communities, and look forward to its continued growth in Virginia.”
“Virongy Biosciences Inc. chose Virginia as its company location mainly because it is inside the rapid-growing biotech park of Prince William County, and right beside the Science and Technology Campus of George Mason University,” said Virongy’s Chief Scientific Officer Brian Hetrick.
“I toured the Virongy Biosciences lab at the Northern Virginia Bioscience Center’s grand opening in March, and I was impressed not only by the important discoveries from the Virongy team, but moreover the business’ dedication to hiring from and growing the local talent pool of life sciences employees,” said Chair Ann B. Wheeler, Prince William County Board of Supervisors. “Over the last two years, Prince William County saw significant growth and advancement in the biotechnology industry, and this is validation that we are one of the fastest-growing bio-clusters in the state.”
“I’m excited to see the expansion of a critical arm of the healthcare sector as we continue to build on our successful local economy in Prince William,” said Senator Jeremy S. McPike. “I look forward to working with Virongy.”
“The field of bioscience has made great strides in the last several years,” said Delegate Michelle Maldonado. “With Northern Virginia’s Bioscience Center here in District 50, we are joining this conversation with critical research, contributions, and impact for the Commonwealth through jobs, health solutions, and more. I am excited for Virongy’s expansion in our community and look forward to partnering together for the benefit of all Virginians.”
Established in 2014, Virongy focuses on creating cutting-edge technologies in virology, viral vector-based gene therapy, virus-host cell biology, and viral immunology. The company develops new technologies that can be used for scientific discoveries, clinical diagnostics, and disease treatment. Virongy has discovered and developed key technologies and products including rapid quantitative COVID-19 neutralizing antibody test, Infectin, Cellment, HIV Rev-dependent Lentiviral Vector, and HIV drug and neutralizing antibody discovery technologies. The company’s mission is to provide scientists and clinicians with innovative technologies for studying viruses and viral vectors, and to provide virological services that meet the highest academic and industry standards, facilitating scientific discoveries, clinical diagnostics, and disease treatment.
The Virginia Economic Development Partnership worked with Prince William County to secure the project for Virginia and will support Virongy’s job creation through the Virginia Jobs Investment Program (VJIP), which provides consultative services and funding to companies creating new jobs in order to support employee recruitment and training activities. As a business incentive supporting economic development, VJIP reduces the human resource costs of new and expanding companies. VJIP is state-funded, demonstrating Virginia’s commitment to enhancing job opportunities for citizens.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and